Breaking News

OcyonBio, Biosimilar Solutions to Begin GMP Mfg. in Puerto Rico

The plant in Aguadilla will include more than 95,000 sq.-ft. of cleanroom and biomanufacturing space, with biosimilar production scheduled in 2022.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

OcyonBio entered a manufacturing and operations agreement to develop biosimilar drug product facilities for Biosimilar Solutions, Inc. OcyonBio is creating an advanced therapy contract development, manufacturing organization (CDMO) that provides preclinical through commercial manufacturing including process development, plasmid DNA, viral vectors, cell banking, cell processing, and supporting testing capabilities.   The plant in Aguadilla will include more than 95,000 sq.-ft. of cleanroom and ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters